BIAL
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
the purpose of this study is to determine the effect of age on the Pharmacokinetics (PK) profile of BIA 5-1058 at steady state after multiple oral doses
Full description
This was a single-centre, open-label, parallel group, non-randomised, two-part multiple dose 10-day study in healthy young and elderly male and female subjects. The study comprised a screening evaluation between 2 and 28 days before the first Investigational Medicinal Product (IMP) administration, a hospitalisation period of 15 days comprising a treatment period of 10 days, and a follow-up visit approximately 7 days after discharge.
Part 1: Subjects received 1200 mg of BIA 5-1058 once a day (od), in fasting conditions, for 10 days Part 2 : Subjects received 400 mg of BIA 5-1058 od, in fasting conditions, for 10 days.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
All subjects (young and elderly):
A signed and dated informed consent form before any study-specific screening procedure was performed;
Healthy male and female subjects as determined by the Investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs and digital 12-lead electrocardiogram (ECG);
Non-smoker or ex-smokers for at least 3 months at screening;
BMI between 18 and 30 kg/m2, inclusive;
Negative tests for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus antibodies (HCV Ab) and anti-human immunodeficiency virus antibodies (HIV-1 and HIV-2 Ab) at screening;
Clinical laboratory test results clinically acceptable at screening and admission to the study;
Negative screen for alcohol and drugs of abuse at screening and admission to the study;
If male:
Using an effective method of contraception with a pregnant partner or partner of childbearing potential (condom or occlusive cap [diaphragm or cervical or vault caps] with spermicidal foam or gel or film or cream or suppository; true abstinence; or vasectomy) throughout the study;
Refraining from donating sperm throughout the study.
Young subjects only:
Males and females aged between 18 and 40 years, inclusive.
If female:
No childbearing potential by reason of surgery or at least 1 year post-menopause (i.e., 12 months post last menstrual period), or menopause confirmed by follicle-stimulating hormone (FSH) testing;
If of childbearing potential, using an effective non-hormonal method of contraception [intrauterine device or intrauterine system; condom or occlusive cap (diaphragm or cervical or vault caps) with spermicidal foam or gel or film or cream or suppository; true abstinence; or vasectomized male partner, provided that he is the sole partner of that subject] for all the duration of the study;
If of childbearing potential, negative serum pregnancy test at screening and negative urine pregnancy test on admission to the study.
Elderly subjects only:
Males and females older than 65 years, inclusive.
Exclusion criteria
All subjects (young and elderly):
Clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders;
Clinically relevant surgical history;
History of relevant atopy or drug hypersensitivity;
History of alcoholism or drug abuse;
Consumption of more than 14 units of alcohol a week [1 unit corresponds to 1 glass of 12° wine (10 cL), 1 glass of 45° pastis (2.5 cL), 1 glass of 40° whisky (2.5 cL), 1 glass of 12° champagne (10 cL), 1 glass of 18°aperitif drink (7 cL) or one 25-cL glass of 5°beer];
Significant infection or known inflammatory process at screening or admission to study;
Acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to the study;
Previous use of BIA 5-1058;
Use of any investigational drug or participation in any clinical trial within 90 days prior to screening;
Participation in more than 2 clinical trials within the 12 months prior to screening;
Donation or reception of any blood or blood products within the 3 months prior to screening;
Vegetarians, vegans or other medical dietary restrictions;
Not able to communicate reliably with the Investigator;
Unlikely to co-operate with the requirements of the study.
If male:
Not using an accepted effective method of contraception;
Refusing to refrain from donating sperm throughout the study.
Young subjects only:
Use of medicines within 2 weeks of admission that could affect the safety or other study assessments, in the Investigator's opinion;
If female of childbearing potential:
Pregnant or breastfeeding;
Not using an accepted effective contraceptive method or using oral contraceptives.
Elderly subjects only:
For elderly subjects, previously prescribed medications that interfered with absorption, distribution, metabolism, and excretion or safety/tolerability evaluation of BIA 5-1058 and adrenal or renal function were prohibited; however, previously prescribed medications that did not interfere with absorption, distribution, metabolism, and excretion or safety/tolerability evaluation of BIA 5-1058, adrenal or renal function and which could not interfere with the objectives of the study were allowed if the dose regimen had been stable for at least 4 weeks and was expected to remain stable throughout the study. Such concomitant medications were to be reviewed and mutually agreed upon by the Sponsor and the Investigator.
Primary purpose
Allocation
Interventional model
Masking
61 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal